C3-Targeting dsRNA Composition for Accessible Complement Suppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There are limited therapies available for treating complement component C3-associated diseases, which often require invasive and costly administration, and inappropriate activation of the complement system contributes to various pathological conditions.

Innovation Solution

Development of double-stranded ribonucleic acid (dsRNA) agents that target and inhibit the expression of complement component C3 by mediating RNA-induced silencing complex (RISC)-mediated cleavage of C3 RNA transcripts, utilizing specific nucleotide sequences and modifications to enhance efficacy and stability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional therapies for complement component C3-associated diseases are used, then treatment effectiveness is achieved, but administration is invasive and costly

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidadministration accessibility

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces conventional mechanical/invasive administration methods with RNA-based molecular therapy. The dsRNA agents target C3 mRNA through RNA interference mechanisms, eliminating the need for invasive procedures while maintaining treatment effectiveness against complement component C3-associated diseases

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If dsRNA agents are designed with high sequence complementarity to C3 mRNA, then gene silencing efficacy is improved, but off-target effects may increase

Engineering Contradiction:

Improvegene silencing efficacyVSAvoidoff-target effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing dsRNA agents with specific sequence characteristics in different regions. The sense and antisense strands are engineered with particular complementarity patterns that concentrate silencing activity on the target C3 mRNA while minimizing off-target binding through controlled mismatch distributions in specific local regions

Inventive Principle:

Principle #3Local quality

3Area of stationary object

If dsRNA agents are administered systemically, then broad coverage is achieved, but non-specific complement activation may occur

Engineering Contradiction:

Improvetissue coverageVSAvoidnon-specific complement activation

Core Design Contradiction:

Area of stationary objectVSObject-generated harmful factors

Solution Approach 1:

The patent uses dsRNA agents as intermediaries that specifically bind to C3 mRNA through base pairing. This molecular intermediary approach allows systemic administration with broad tissue coverage while maintaining specificity through RNA-RNA hybridization, preventing non-specific complement activation that would occur with direct complement targeting

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The dsRNA agents effectively inhibit C3 expression, reducing protein levels and alleviating symptoms of associated disorders such as cold agglutinin disease and paroxysmal nocturnal hemoglobinuria, providing a more accessible and effective therapeutic option.

Implementation Method 1

double stranded ribonucleic acid (dsRNA) agents that target and inhibit the expression of complement component C3 by mediating RNA-induced silencing complex (RISC)-mediated cleavage of C3 RNA transcripts

Methodology Applied

Scientific EffectRNA interference (RNAi):

Data Source

PatentUS20260049312A1Complement component c3 irna compositions and methods of use thereof

Publication Date: 2026.02.19 ALNYLAM PHARMACEUTICALS INC

AI summary

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the complement component C3 gene (C3). The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., cold agglutinin disease (CAD), warm autoimmune hemolytic anemia, and paroxysmal nocturnal hemoglobinuria (PNH), lupis nephritis (LN), bullous pemphigoid, pemphigus, e.g., pemphigus vulgaris (PV) and pemphigus foliaceus (PF), and C3 glomerulopathy.